Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empirical steroids and/or antifungals in immunocompromised patients with acute respiratory failure from undetermined etiology
2019-002569-37Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute respiratory decompensation, immunocompromise and mycoses comparing Empirical methylprednisolone with Empirical methylprednisolone + isavuconazole (2 arms). Primary endpoint: All-cause day-90 mortality. Started Jan 2020; status: active.
02
Drugs
methylprednisoloneisavuconazole
03
Conditions
acute respiratory decompensationimmunocompromisemycoses
Beyond the preview
Go deeper on 2019-002569-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002569-37.